Study drug for advanced prostate cancer after standard treatments
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by pathology, and it is adenocarcinoma (not the rare “pure small cell” type)
- Your cancer is metastatic and has become “castration-resistant” (it keeps growing even though testosterone is blocked)
- Your PSA is at least 4 ng/mL at screening AND the cancer has progressed within the last 6 months based on PSA rise and/or scans
- You have already tried at least 2 prior treatments for metastatic/castration-resistant prostate cancer, including at least one newer anti-androgen medicine (like abiraterone, enzalutamide, apalutamide, or darolutamide)
- You have not had certain recent biologic (immune-type) therapies close to study start, and you are recovered from side effects
- You do not have specific immune-related problems (like certain autoimmune diseases), serious brain/nerve conditions, or uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This trial tests a combination of two drugs (REGN5678 and cemiplimab) for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to see if this new combination can help shrink the cancer or slow its growth.
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.